Oraxol (Oral Paclitaxel) is an oral formulation of Paclitaxel developed by Athenex that is administered with a second drug (HM30181A) to promote absorption of paclitaxel in the gastrointestinal tract. The World Health Organization has designated Paclitaxel as a critical anti-cancer drug,. We believe an oral form of paclitaxel will be a major advance in the treatment of cancer, and are rapidly advancing our lead Orascovery drug candidate, Oraxol. In 2015, we started enrolling patients in a Phase 3 Oraxol study in a head to head comparison with the standard IV formulation of paclitaxel. The first interim analysis from this Phase 3 study in metastatic breast cancer is expected in 2017. In October 2016, we entered into a clinical study collaboration with Eli Lilly and Company to evaluate Oraxol in combination with Lilly’s approved monoclonal antibody Cyramza (ramucirumab) to treat gastric, gastric- esophageal and esophageal cancer. The ability to dose paclitaxel orally is expected to provide flexibility in the design and optimization of combination regimens, resulting in further advances in the treatment of cancer.